ARQT — Arcutis Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00- $2.50bn
- $2.42bn
- $196.54m
- 49
- 14
- 99
- 54
Annual income statement for Arcutis Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 3.69 | 59.6 | 197 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 2.93 | 54.6 | 177 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 137 | 207 | 305 | 301 | 325 |
| Operating Profit | -137 | -207 | -302 | -241 | -128 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -136 | -206 | -311 | -259 | -139 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -136 | -206 | -311 | -262 | -140 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -136 | -206 | -311 | -262 | -140 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -136 | -206 | -311 | -262 | -140 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.8 | -4.18 | -5.66 | -3.78 | -1.16 |